NIAID said it awarded 14 grants totaling US$7.8 million in first-year funding for “basic research to identify new approaches for designing a safe and effective HIV vaccine.” The grants were awarded under the Innovation for HIV Vaccine Discovery (IHVD) initiative, which is expected to receive up to $34.8 million over the next four years. NIAID Director Anthony S. Fauci, M.D. commented, “Recent discoveries about the basic biology of HIV and how the virus adapts to its host have provided useful information and new opportunities to guide vaccine development. These grants are designed to build on that information and stimulate discovery of new ways to design a robust vaccine that prevents acquisition and establishment of latent infection.” The 14 IHVD grant recipient organizations include:
– Altravax Inc. (Sunnyvale, Calif.)
– Catholic University of America (Washington, D.C.)
– Dartmouth College (Hanover, N.H.)
– Duke University (Durham, N.C.)
– Harvard Medical School (Boston)
– Massachusetts General Hospital (Boston)
– NYU Langone Medical Center (New York City)
– University of California (Irvine)
– University of Maryland (Baltimore)
– University of Medicine and Dentistry of New Jersey (Newark)
– University of Minnesota (Minneapolis)
– University of North Carolina (Chapel Hill)
– University of Rochester (Rochester, N.Y.)
– University of Texas at El Paso
vaccines and global health :: ethics and policy 